ZA200808744B - Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions - Google Patents

Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Info

Publication number
ZA200808744B
ZA200808744B ZA200808744A ZA200808744A ZA200808744B ZA 200808744 B ZA200808744 B ZA 200808744B ZA 200808744 A ZA200808744 A ZA 200808744A ZA 200808744 A ZA200808744 A ZA 200808744A ZA 200808744 B ZA200808744 B ZA 200808744B
Authority
ZA
South Africa
Prior art keywords
rnai
tyrosine kinase
inflammatory conditions
mediated inhibition
spleen tyrosine
Prior art date
Application number
ZA200808744A
Other languages
English (en)
Inventor
John M Yanni
Jon E Chatterton
Daniel A Gamache
Steven T Miller
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of ZA200808744B publication Critical patent/ZA200808744B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200808744A 2006-04-13 2008-10-14 Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions ZA200808744B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79184706P 2006-04-13 2006-04-13

Publications (1)

Publication Number Publication Date
ZA200808744B true ZA200808744B (en) 2009-12-30

Family

ID=38610402

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808744A ZA200808744B (en) 2006-04-13 2008-10-14 Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Country Status (13)

Country Link
US (4) US8048863B2 (enExample)
EP (3) EP3156486A3 (enExample)
JP (1) JP2009533475A (enExample)
KR (1) KR20080110900A (enExample)
CN (2) CN101972483A (enExample)
AR (1) AR060448A1 (enExample)
AU (2) AU2007238027B2 (enExample)
BR (1) BRPI0709506A2 (enExample)
CA (1) CA2649138C (enExample)
MX (2) MX2008013068A (enExample)
TW (2) TW200808360A (enExample)
WO (1) WO2007121347A2 (enExample)
ZA (1) ZA200808744B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046059A1 (en) * 2007-10-01 2009-04-09 Alcon Research, Ltd. Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
US20110123637A1 (en) * 2008-05-26 2011-05-26 Universitat Zurich Protamine/rna nanoparticles for immunostimulation
AU2009330458B2 (en) * 2008-12-22 2013-08-22 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
CN104805085A (zh) 2014-01-29 2015-07-29 江苏命码生物科技有限公司 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用
SG11201705312PA (en) * 2014-12-29 2017-07-28 Bonac Corp Composition containing nucleic acid molecule stably
US10888391B2 (en) 2015-05-29 2021-01-12 Ablacon Inc Optical force sensing assembly for an elongated medical device
CA3002786C (en) 2015-10-30 2021-09-07 Bonac Corporation Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-.beta.1 gene
BR102018001541B1 (pt) 2018-01-24 2021-05-11 Universidade Federal Do Rio Grande Do Sul composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360720A (en) 1993-10-08 1994-11-01 Alcon Laboratories, Inc. Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
JPH11507824A (ja) * 1995-06-07 1999-07-13 ユニバーシティー・オブ・ペンシルバニア 食作用を阻害する方法
CA2526831C (en) * 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
JP4649331B2 (ja) * 2002-10-01 2011-03-09 エピゲノミクス アーゲー 乳房細胞増殖障害の改良治療方法および核酸
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
CN101914532A (zh) * 2002-11-22 2010-12-15 生物智囊团株式会社 Rna干扰的目标碱基序列的搜索方法
AU2003224132A1 (en) * 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
EP2371835A1 (en) * 2003-07-03 2011-10-05 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
CA2546074A1 (en) * 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
GB0404209D0 (en) 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
WO2005085443A2 (en) * 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
EP1904649A2 (en) 2005-07-18 2008-04-02 Epigenomics AG Compositions and methods for cancer diagnostics comprising pan-cancer markers
WO2007070872A1 (en) * 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
TW200916117A (en) 2007-08-03 2009-04-16 Alcon Res Ltd RNAi-related inhibition of TNF α signaling pathway for treatment of ocular angiogenesis

Also Published As

Publication number Publication date
EP2662446A3 (en) 2014-04-02
CN101972483A (zh) 2011-02-16
BRPI0709506A2 (pt) 2011-07-19
CN101443020A (zh) 2009-05-27
WO2007121347A3 (en) 2008-12-04
EP3156486A2 (en) 2017-04-19
US20140357695A1 (en) 2014-12-04
US20110288157A1 (en) 2011-11-24
TW201336514A (zh) 2013-09-16
AU2007238027A1 (en) 2007-10-25
EP2004240A2 (en) 2008-12-24
CA2649138A1 (en) 2007-10-25
KR20080110900A (ko) 2008-12-19
EP2004240A4 (en) 2010-12-15
US8865671B2 (en) 2014-10-21
AU2013207601B2 (en) 2016-11-17
AU2007238027B2 (en) 2013-08-15
MX2008013068A (es) 2008-12-16
MX345954B (es) 2017-02-16
US9371529B2 (en) 2016-06-21
US8048863B2 (en) 2011-11-01
CA2649138C (en) 2018-04-03
US20160257963A1 (en) 2016-09-08
TW200808360A (en) 2008-02-16
AR060448A1 (es) 2008-06-18
JP2009533475A (ja) 2009-09-17
EP2662446A2 (en) 2013-11-13
EP3156486A3 (en) 2017-07-12
US20090324507A1 (en) 2009-12-31
WO2007121347A2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
AU2013207601A1 (en) RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
ZA200808744B (en) Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
HRP20181622T1 (hr) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
HRP20180611T1 (hr) Postupci smanjenja razina bazofila
ZA200809203B (en) Rnai-mediated inhibition of tumor necrosis factor alpha-related conditions
GB2444207B (en) Installation of offshore structures
GB2460172B (en) Installation of structures in water
GB0625070D0 (en) Characterization of molecules
ZA200903233B (en) Quinazolines for PDK1 inhibition
ZA200808307B (en) Quinazolines for PDK1 inhibition
IL195803A0 (en) Compositions and methods for sirna inhibition of angiogenesis
EP2083861A4 (en) ANTAGONISTS OF PCSK9
EP2106261A4 (en) ANTAGONISTS OF PCSK9
EP1978966A4 (en) TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
IL196337A0 (en) Tyrosine kinase inhibitors
PT2222330T (pt) Tratamento de doenças inflamatórias com ace2
GB0621607D0 (en) Inhibitors of c-Met
ZA200809874B (en) Method of inhibiting c kit kinase
GB2447028B (en) Inhibition of corrosion of structures
GB2437540B (en) Fastening of pipes
TWM298600U (en) Improved structure of clothespin set
GB0805693D0 (en) Combinations of P13-delta and P13-gamma kinase inhibitor compounds
IL196822A0 (en) Polycyclic dianthraquinones as inhibitors of inflammatory cytokines
EP2046314A4 (en) POLYCYCLIC DIANTHRAQUINONES AS INHIBITORS OF INFLAMMATORY CYTOKINES
GB0715788D0 (en) Inhibition of corrosion